Maprotiline

Maprotiline Brand names, Maprotiline Analogs

Maprotiline Brand Names Mixture

No information avaliable

Maprotiline Chemical_Formula

C₂₀H₂₃N

Maprotiline RX_link

No information avaliable

Maprotiline fda sheet

Maprotiline msds (material safety sheet)

Maprotiline MSDS

Maprotiline Synthesis Reference

M. Wilhelm, et al. Helv. Chim. Acta. 52, 1385 (1969)

Maprotiline Molecular Weight

277.403 g/mol

Maprotiline Melting Point

93 ^oC

Maprotiline H₂O Solubility

Slightly soluble

Maprotiline State

Solid

Maprotiline LogP

5.546

Maprotiline Dosage Forms

Tablet (10, 25, 50, and 75mg film coated)

Maprotiline Indication

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Maprotiline Pharmacology

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline re-uptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Maprotiline Absorption

Completely absorbed following oral administration

Maprotiline side effects and Toxicity

LD₅₀=~900 mg/kg (Orally in rats); LD₅₀=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

Maprotiline Patient Information